Our Science – FitzGerald Website
David J. FitzGerald, Ph.D.
Selected Publications |
 |
| 1)
Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 121: 1165-74, 2013. [Journal] |
|
| 2)
Liu XF, Fitzgerald DJ, Pastan I. The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin. Cancer Res. 73: 2281-8, 2013. [Journal] |
|
| 3)
Mattoo A, Fitzgerald DJ. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant Small Cell Lung Cancer cell lines. Int J Cancer. [Epub ahead of print], 2012. [Journal] |
|
| 4)
Wei H, Xiang L, Wayne AS, Chertov O, Fitzgerald DJ, Bera TK, Pastan I. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc. Natl. Acad. Sci. U.S.A. 109: 6898-903, 2012. [Journal] |
|
| 5)
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. J. Clin. Oncol. 30: 1822-8, 2012. [Journal] |
|
| 6)
Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk. Lymphoma. 52 Suppl 2: 79-81, 2011. [Journal] |
|
| 7)
Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011. [Journal] |
|
| 8)
Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011. [Journal] |
|
| 9)
FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 71: 6300-9, 2011. [Journal] |
|
| 10)
Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, Fitzgerald DJ. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol. Cancer Ther. 9: 2007-15, 2010. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/9/2013.
